

ARTICLE

A novel locus for episodic ataxia: *UBR4* the likely candidate

Judith Conroy¹, Paul McGettigan², Raymond Murphy³, David Webb⁴, Sinéad M Murphy³, Blathnaid McCoy⁴, Christine Albertyn³, Dara McCreary¹, Cara McDonagh³, Orla Walsh⁴, SallyAnn Lynch^{1,4,5} and Sean Ennis^{2,6}

Episodic ataxias (EAs) are rare neurological channelopathies that are characterized by spells of imbalance and a lack of co-ordination. There are seven clinically recognized EAs and multiple isolated cases. Five disease-causing genes have been identified to date. We describe a novel form of autosomal dominant EA in a large three-generation Irish family. This form of EA presents in early childhood with periods of unsteadiness generalized weakness and slurred speech during an attack, which may be triggered by physical tiredness or stress. Linkage analysis undertaken in 13 related individuals identified a single disease locus (1p36.13-p34.3) with a LOD score of 3.29. Exome sequencing was performed. Following data analysis, which included presence/absence within the linkage peak, two candidate variants were identified. These are located in the *HSPG2* and *UBR4* genes. *UBR4* is an ubiquitin ligase protein that is known to interact with calmodulin, a Ca²⁺ protein, in the cytoplasm. It also co-localizes with *ITPR1* a calcium release channel that is a major determinant of mammal co-ordination. Although *UBR4* is not an ion channel gene, the potential for disrupted Ca²⁺ control within neuronal cells highlights its potential for a role in this form of EA.

European Journal of Human Genetics (2014) 22, 505–510; doi:10.1038/ejhg.2013.173; published online 28 August 2013

Keywords: episodic ataxia; exome sequencing; brain; linkage analysis; *UBR4*; *HSPG2*

INTRODUCTION

Episodic ataxias (EAs) are rare neurological channelopathies that are characterized by spells of imbalance and a lack of co-ordination. Affected individuals may also experience nystagmus, myokymia, epilepsy and/or tinnitus. Clinical and genetic heterogeneity is not uncommon, and a number of EA subtypes have been described (see Table 1 for further information). The most common EA subtypes (1 and 2) have been described in multiple families. They are caused by mutations in the potassium and calcium channel genes, *KCNA1* and *CACNA1A*.^{1,2} Mutations in *CACNB4* and *SLC1A3* cause EA5 and EA6.^{3,4} Further, mutations in *PRRT2* have been identified in a single patient who also presents with hemiplegic migraines⁵ and in two brothers with familial paroxysmal kinesigenic dystonia in addition to learning disabilities, absences and EA.⁶ The *PRRT2* protein has been shown to interact with the *SNAP25* protein that has a major role in synaptic exocytosis.⁷ This observation demonstrates that ion channel dysfunction is not the sole mechanism for developing EA. Novel loci have also been identified for EA3 (1q42) and EA7 (19q13), although the defective genes remain to be identified. Additional forms of EA with phenotypes that are not consistent with those reported with the previously identified genes/loci have also been reported (EA4 and isolated EA cases).⁸ Many patients do not have mutations in the known EA genes. It is clear that new genes remain to be discovered.

In this report, we describe an autosomal dominant EA that differs in clinical and genetic features from previously described EAs. Parametric linkage analysis ruled out all previously loci reported for EA. A single novel locus was identified on chromosome 1p36.13-p34.3.

This peak spanned 18.5 Mb, 281 RefSeq genes and 10 miRNAs. This linkage finding confirms that differences in clinical presentation are due to a genetic defect in a previously unreported gene, highlighting the existence of yet another form of episodic ataxia.

PATIENTS AND METHODS

Patients

This family was referred to the clinical genetic service for genetic assessment at the National Centre of Medical Genetics, Ireland. Thirteen family members in three generations are affected by EA (see Figure 1). In total, 13 of these individuals (I-2, II-3, II-5, II-6, II-7, II-10, II-18, III-5, III-6, III-7, III-8 and III-12) attended either the Adelaide and Meath Hospital, incorporating the National Children's Hospital or the National Children's Hospital for Sick Children for full clinical assessment. A DNA sample was also obtained for individual II-17. Clinical mutation screening of *KCNA1*, *CACNA1A*, and (CAG)_n repeats in *SCA1*, *SCA2*, *SCA3* and *SCA6* revealed no causative mutation. Ethical approval for this study was granted by the Adelaide and Meath Hospital, incorporating the National Children's Hospital and informed consent was received for each individual involved.

Clinical presentation

The symptoms of EA become apparent in this family in the second year of life as the children learn to walk. Attacks are characterized by unsteadiness, generalized weakness and slurred speech, which may be triggered by physical tiredness or stress. They do not suffer tinnitus or epilepsy although two of the affected individuals have migraine without aura. The number of attacks varies between family members and indeed throughout life. Some family members suffer up to two attacks per day, whereas others can go months without an

¹Temple Street Children's University Hospital, Temple Street, Dublin, Ireland; ²University College Dublin, Belfield, Dublin, Ireland; ³The Adelaide and Meath Hospital, incorporating the National Children's Hospital (AMNCH), Tallaght, Dublin, Ireland; ⁴Our Lady's Children's Hospital, Crumlin, Dublin, Ireland; ⁵National Centre for Medical Genetics, Our Lady's Hospital for Sick Children, Crumlin, Dublin, Ireland and ⁶The Academic Centre on Rare Diseases, University College Dublin, Belfield, Dublin, Ireland
*Correspondence: Dr S Ennis, Academic Centre on Rare Diseases, University College Dublin, Belfield, Dublin 4, Ireland. Tel: +353 1 716 6685; Fax: +353 1 716 6651; E-mail: Sean.Ennis@ucd.ie

Received 27 February 2013; revised 9 May 2013; accepted 26 June 2013; published online 28 August 2013

Table 1 Comparison of Irish EA to previously reported EA

	EA1	EA2	EA3	EA4	EA5	EA6	EA7	Other EAs	Irish Familial EA
OMIM	160120	108500	606554	606552	613855	612656	611907	unassigned	unassigned
Attack duration	seconds to min	hours	1 min to 6 h	brief	hours	hours-days	hours-days	hours to days	min to 24 h
Age of onset	2–15	2–20	1–42	23–60	3 to teen	5	<20 years	After 30	Early infancy
Myokymia	Usual	No	Usual	No	No	No	No	No	Occasionally
Nystagmus	No	Usual	Occasional	Usual	Usual	No	No	Usual	Occasionally
Slurred speech (needs checking)	Occasional	No	No	No		Occasional	No	NA	Yes
Epilepsy	Occasional	Infrequent	Occasional	Occasional	Usual	Yes	No	No	No
Tinnitus	Infrequent	No	Usual	Occasional	No	No	No	No	No
Acetazolamide	Occasional	Usual	Usual	No	Transient	No	Unknown	Occasional	No
Inheritance	AD	AD	AD	AD	AD	Sporadic	AD	Multiple	AD
Chr locus	12q13	19p13	1q42	Unknown	2q22-q23	5p13.2	19q13	Unknown	1p36.13-p34.3
Mutated gene	<i>KCNA1</i>	<i>CACNA1A</i>	Unknown	Unknown	<i>CACNB4</i>	<i>SLC1A3</i>	Unknown	Unknown	Unknown
Mutated protein	Kv1.1	Cav2.1	Unknown	Unknown	Cav2.1	EAATI	Unknown	Unknown	Unknown

Abbreviations: AD, autosomal dominant; EA, episodic ataxia.

Although a number of similarities exist between this form of EA and more common forms of EA, some differences do occur. These include the early age of onset and long duration of attacks. Slurred speech also occurs in all affected individuals within this pedigree and treatment with acetazolamide is of no effect. Interictal findings vary between individuals.




Figure 1 Irish family presenting with novel form of autosomal dominant episodic ataxia. DNA from the 13 family members identified above was available for molecular analysis (I-2, II-3, II-5, II-6, II-7, II-10, II-17, II-18, III-5, III-6, III-7, III-8 and III-12, marked by a black star or a white star on a black background). Exome sequencing was performed on six of these samples (I-2, II-3, II-6, II-7, III-6 and III-12, represented by a white star on a black background).

attack. In some cases, the frequency and severity of attacks appear to lessen with increasing age and, in one case, lessened during pregnancy. Attacks are eased by clonazepam. None of the affected individuals responded to acetazolamide. The disorder is not progressive in nature, although most have mild intention tremor and impaired tandem gait interictally, which remains asymptomatic; I-2 is now in her 70s and remains asymptomatic between attacks despite mild abnormalities on examination. One individual (II-12) had a MRI brain scan twice, at age 19 and again at age 29 years. Both were normal. Specifically, there were no cerebellar abnormalities observed. Information describing the family is presented in Table 2, and one affected individual is reported here in detail.

Patient II-6 was 45 years old when first seen and described attacks since the age of 2 years. Attacks were usually triggered by anxiety, stress, cold weather or physical fatigue, and each attack would last between 10 min and 12 hours. An attack would be preceded by a 'warning' feeling, which she found difficult to describe. She would then develop generalized weakness associated with slurred speech and imbalance, which would prevent her walking. She also described twitching around the eyes and mouth, which occurred during an attack but could also occur independently of an attack. Attacks occurred up to twice daily. In between attacks, she felt normal. She also described migrainous headaches that occurred on a weekly basis. On examination, there was eyelid myokymia, mild dysarthria and intention tremor of both upper limbs. Tandem gait was mildly impaired. Power, sensation and reflexes were normal.

Although there are a number of similarities between the features in this family to the other EA subtypes (EA1–EA7), some differences also exist. The onset of symptoms, usually by age 2 years, is much earlier than that in EA 1–7. In comparison with EA1, attacks are much longer, and there is no muscle hypertrophy. In addition, there is no kinesigenic provocation or limb or neck

jerking during attacks. This family does not report vertigo and tinnitus, features of EA3. Although some affected individuals have minimal gaze-evoked nystagmus, prominent eye movement abnormalities such as those seen in EA2 and EA4 are not seen. Acetazolamide is not effective in these patients; however, they demonstrate a clear response to clonazepam.

SNP genotyping and linkage analysis

DNA from the 13 family members identified above was available for molecular analysis. Genomic DNA was extracted from peripheral blood and genotyped for over 300 000 markers on the HumanCytoSNP-12 microarray using the recommended protocol. Samples were processed on an Illumina BeadStation 500GX platform (Illumina, San Diego, CA, USA) using default settings. Analysis and genotype calling were performed using the IlluminaBeadStudio software v3.3.7 (Illumina). Experimental quality control was assessed using the sample independent and sample dependent Illumina internal controls.

Data cleaning was performed using Plink v1.06.⁹ Samples were excluded if the call rate was <95%. SNPs were excluded based on missingness (100% call rate required), Hardy–Weinberg equilibrium (<0.001), minor allele frequency (<10%) and the presence of Mendel errors. Following this, the data was thinned to 20%. Pairwise linkage analysis was undertaken using Merlin 1.1.2.¹⁰ An autosomal dominant model with high penetrance (0.99) and low disease allele frequency (0.0001) was assumed.

Exome sequencing and data analysis

DNA from six family members (I-2, II-3, II-6, II-7, III-6 and III-12) was selected for whole-exome sequencing, which was performed at Atlas Biolabs (<http://www.atlas-biolabs.de>). The exome of each individual was enriched and

Table 2 Clinical presentation of patients with EA in Irish pedigree

	<i>I-2</i>	<i>II-6</i>	<i>II-10</i>	<i>II-17</i>	<i>II-18</i>	<i>II-1</i>	<i>II-4</i>
Attended clinical review	Y	Y	Y	Y	Y	N/A	N/A
Attack duration	minutes to hours	10 min to 12 h	30 min to 6 h	2 min to 10 h	<2 h		
Attack frequency	Varies from 0/month to 3 or 4 per week in clusters	2/day	1/day	1-2/day	daily	Daily	U
<i>Characteristics of attack</i>							
Muscle weakness	Y	Y	Y	Y	Y	Y	Y
Slurring of speech	Y	Y	Y	Y	Y	Y	Y
Poor balance	Y	Y	Y	Y	Y	Y	Y
Twitching around eyes		Y	Y		Y		
Response to clonazepam	Y	Y	Y	Y	U	Y	U
Additional information	Frequency of episodes is decreasing with age					Frequency of episodes has reduced with age	
EA during pregnancy	U	No pregnancies	Marked improvement		Marked improvement		no pregnancies
<i>Interictal examination findings</i>							
Nystagmus	Y	N	Y	N	N		
Gait ataxia	Y	Y	Y	N	Y		
Myokymia	N	Y	N	N	N		
Dysarthria	N	Y	Y	N	Y		
Tremor	Y	Y	Y	Y	Y		
Additional interictal symptoms	N	Myokymia, migraine, depression	Migraine	N	Depression	N	N
	<i>II-12</i>	<i>II-13</i>	<i>II-15</i>	<i>III-6</i>	<i>III-8</i>	<i>III-12</i>	
Attended clinical review	N/A	N/A	N/A	Y	Y	Y	
Attack duration				10 min–1 day	10–15 min		
Attack frequency	2/day	U	Several/day	2/day	Weekly	2/month	
<i>Characteristics of attack</i>							
Muscle weakness	Y	Y	Y	Y	Y	Y	Y
Slurring of speech	Y	Y	Y	Y	Y	Y	Y
Poor balance	Y	Y	Y	Y	Y	Y	Y
<i>Twitching around eyes</i>							
Response to clonazepam	Y	U	Y	Y	U	Y	
Additional information	Attacks have become more severe with age						
EA during pregnancy			Marked improvement		No pregnancies		
<i>Interictal examination findings</i>							
Nystagmus	N/A	N/A	N/A		N	N	N
Gait ataxia				N	N	Y	
Myokymia				N	N	N	
Dysarthria					N		
Tremor				Y	N	Y	
Additional interictal symptoms	N	N	N	N	N	N	N

Abbreviations: N, no; N/A, data not available; U unknown; Y, yes.

All patients developed symptoms of EA in early infancy. Many of the individuals suffer at least one attack per day, however the frequency and severity of attacks lessens with increasing age. No individual responded to acetazolamide but the attacks are eased by clonazepam.

sequenced using the Human EZ Exome Enrichment kit (Roche NimbleGen, Madison, WI, USA) and HiSeq platform (Illumina). Single-sequence reads were aligned to the hg18 reference genome using the Burrows–Wheeler Alignment tool version 0.5.7.¹¹ PCR duplicates and low-quality sequences (Q<20) were excluded. GATK¹² was used to recalibrate the quality scores for the aligned reads. Fivefold coverage was required for inclusion in analysis. Variants and indels were identified by SAMtools.¹³ Variants were annotated using the software ANNOVAR.¹⁴ All chromosome locations are based on the

March 2006 (NCBI36/hg18) assembly. For regions with low read depth in linkage peaks, ‘consensus’ affected reads and ‘consensus’ unaffected reads were constructed where individual reads (ie, all affected or all unaffected individuals) were combined into a single read.

As this is an extremely rare form of a highly infrequent dominant disorder, it is very unlikely that any variants reported in other individuals are disease-causing mutations. Therefore, only novel variants were included. Missense, nonsense, frameshift and indels were identified and included for

further analysis. Variants that were present in a heterozygous state in all four affected family members but absent in the two unaffected family members were identified in the first stage of analysis. Variants were further restricted to those present in loci identified in the linkage analysis and excluded if present in our own database of 38 Irish exomes. Variants present in two additional control data sets were excluded. These were (1) the 1000 Genomes Project (<http://www.1000genomes.org/>) and (2) the NHLBI GO Exome Sequencing Project (ESP) (<http://evs.gs.washington.edu/EVS/>). Later analysis included visual inspection of linkage region variants present in three out of four affected individuals to ascertain whether the exclusion was a result of low coverage of the region (ie, to identify potential false negative findings). This was undertaken using the Generic Genome Browser version 2.4.3 (part of the Generic Model Organism suite of genome analysis software tools, http://www.gmod.org/wiki/Main_Page). Variants were also filtered in the absence of the dbSNP database in order to ensure potential disease-causing variants were not excluded because of their presence in this database. A minor allele frequency of 0.1% was selected as the threshold for inclusion/exclusion.

The possible effect of the two candidate mutations was assessed through the use of bioinformatics programmes (Polyphen-2,¹⁵ SIFT,¹⁶ SNAP¹⁷ and PMUT¹⁸). For an average-effect calculation, the values for Polyphen-2 were converted to values from 0 to 1 by dividing all estimates by the max reported value (2.257). For the average calculation, the SIFT values were subtracted from 1 to ensure that the higher scores were associated with the most damaging effect.

RESULTS

Linkage results

The average call rate per sample was 97.96%. Following data cleaning and filtering of SNP data, 30 233 SNPs remained for linkage analysis. The maximum LOD score for this family study was calculated to be 3.3065. Pairwise linkage analysis ruled out all loci previously reported for EA. The highest linkage values for the 2 cM region spanning each EA gene were as follows: *KCNA1* = -14.3, *CACNA1A* = -6.9, *CACNB4* = -10.6, *SLCIA3* = -14.6 and *PRRT2* = -1.3.

One novel locus (LOD = 3.29) was identified on chromosome 1p36.13-p34.3 (18.5 Mb, rs2743201-rs215791) and spanned 283 genes and 10 miRNAs (see Supplementary Table 1 for more information). Linkage maps for all additional chromosomal regions are present in Supplementary Information.

Sequence results

Exome sequencing resulted in an average of 10.88 Gigabases of mappable sequence data per individual, with ~35.6% mapping to the targeted exome. The median targeted exome coverage was 117 fold, and the average percentage of the exome sequenced to 10-fold was 96.8%. Regions with low or zero read depth are detailed in Supplementary Table 2. Following data cleaning, the number of

variants identified per individual ranged from 119 037 to 150 980 (mean = 13 8748, SD = 10 667).

Data were cleaned, filtered and analyzed according to the criteria described in the methods section. Filtering the data according to these criteria and presence within the linkage peaks resulted in a dramatic reduction in the number of candidate disease-causing variants (see Table 3). Initially three candidate variants were identified in the *FCN3*, *HSPG2* and *UBR4* genes. However, literature reviews have identified that the *FCN3* variant (1637delC; rs28357092) has been reported previously.¹⁹ The *FCN3* gene produces a ficolin protein that has a role in the innate immune system. Homozygosity of this variation has been reported in a single individual with immunodeficiency and recurrent infections. Heterozygosity of this variant does not produce any phenotypic effects reminiscent of an ataxic disorder. Therefore, this variant was excluded as a candidate gene for EA.

Two candidate variants remained. The *UBR4* variant (chr1:19277109-19277109) involves a C to T transition that results in an arginine to histidine substitution at amino-acid position 5091. The *HSPG2* variant (chr1:22050646-22050646) involves a T to G transversion leading to a serine to arginine substitution at amino-acid position 2380. The data for variants present in linkage peaks in three out of four affected individuals, while absent in the unaffected individuals, were also analyzed. No additional candidate variants were identified. Filtering of the data based solely on the presence/absence and minor allele frequency using the ESP and 1000 genomes data resulted in the identification of the same two variants (see Supplementary Table 3).

The use of 'consensus' affected and unaffected reads allowed the identification of a single additional variant at chr1:19511144-19511144. This variant (rs148182255) was found to be present with a maf of 0.02 in the 1000 Genomes data. It was excluded from further analysis.

The potential effects of the *HSPG2* and *UBR4* variants were assessed. The *UBR4* variant (average score = 0.812 compared with 0.607 for *HSPG2*) was predicted to be more damaging by each of the prediction programs (see Supplementary Table 4 for more details). All programs reported a non-neutral effect. The *HSPG2* variant was predicted to have no effect using SIFT and PMut. The *UBR4* variant was validated by Sanger sequencing and shown to segregate with the disorder.

DISCUSSION

Seven different EA subtypes have been described to date, with genes and disease loci reported for many (see Table 1 for more details).

Table 3 Summary of variant analysis and segregation with EA phenotype

	Patient 1	Patient 2	Patient 3	Patient 4	Control 1	Control 2	All patients	Not in control
Q20 and 5x coverage	150980	141952	141305	119037	137102	142110	52560	1375
+ Missense, nonsense, frameshift	10326	10391	10373	10132	10352	10320	5229	116
+ Not in dbSNP (version 130)	1269	1319	1304	1258	1283	1319	289	20
+ In candidate linkage regions	14	12	5	7	6	6	4	4
+ Not in Irish control exomes	10	8	3	6	4	5	3	3
+ Not in 1000 genomes or ESP	6	6	3	5	3	3	3	3

Exome sequencing of six family members, four with EA and two without EA identified multiple variants. Data were cleaned and filtered to include variants that were likely to alter protein function and structure, and not previously reported in dbSNP130. To identify candidate disease-causing variants, exome data were analyzed in conjunction with previous linkage analysis. Four variants within the linkage peaks were common to all patients with EA but absent in the unaffected family members. Three of these variants (in *HSPG2*, *UBR4* and *FCN3*) were also absent in individuals in the Irish exome database. The variant in *FCN3* has been previously reported and is not considered a disease-causing candidate variation. The data prioritization method supports the remaining variants as candidate variants for EA.

In this paper, we report a novel form of dominant EA in a large non-consanguineous Irish family. The phenotype is relatively uniform in all affected individuals. The response to clonazepam but not acetazolamide is consistent within affected individuals. Most forms of EA reported to date respond to acetazolamide, possibly because of its effect on carbonic anhydrase causing metabolic acidosis or because of effects on ion channels.^{20,21} Clonazepam is not typically used in EA; however, it has been used successfully in vestibular migraine, a condition suspected to be due to channelopathy in some cases.²² It increases the frequency of chloride ion channel opening, enhancing the inhibitory effect of GABA at the GABA_A receptor;²³ however, it has multiple other central effects. Benzodiazepines have also been shown to have an inhibitory effect on voltage-dependant calcium channels,²⁴ which may be relevant in the setting of the *UBR4* genetic variant that we have described in this family.

Exome sequencing provided the most economic and efficient method for variant screening because of the large number of candidate genes in the single disease locus identified. As expected, exome sequencing confirmed that there were no causative variants in any of the previously identified EA genes. It has been reported that deletions within the *CACNA1A* gene can cause the development of EA.²⁵ If a deletion within *CACNA1A* or indeed any of the previously reported EA genes, a haplotype common to all of the affected family members would surround the gene and the deletion. These haplotypes would be detected by linkage analysis. Linkage scores surrounding the known EA genes (1Mb centromeric and telomeric) were not significant. Variants that were novel, within the linkage peaks and only present in the affected individuals, were limited to just two genes, *HSPG2* and *UBR4*.

In the absence of functional work, it remains possible that the variants reported here are not disease causing but instead are exonic variants of no functional consequence that happen to be present in the linkage peaks identified in the family. A disease-causing variant within an intron or outside the gene may be the true-disease causing one. Expanded repeats are common causes of ataxic disorders, for example, SCA1 and SCA2. However, almost all EA mutations identified to date have been missense or truncating variants. An expanded repeat in the *CACNA1A* gene has been reported in a Korean family in which some affected individuals presented with a phenotype similar to spinocerebellar ataxia 6, others with a phenotype similar to EA2, while other members of the family also had expanded repeats but exhibited no clinical symptoms of either disorder.²⁶ Triplet-repeat disorders often lead to the phenomena of anticipation. No anticipation with regard to age of onset or severity of disorder has been observed in this three-generation family.

The protein produced by *HSPG2* is a heparan sulfate-containing proteo-glycan commonly known as perlecan. It is a large complex protein in the extracellular matrix and has a crucial role in maintaining the structure and function of the neuromuscular junction and vascular system. In humans, mutations in this gene have been reported in two recessive disorders, Schwartz–Jampel syndrome type 1 (SJS, OMIM 255800)^{27,28} and Silver–Handmaker type of dyssegmental dysplasia (DDSH, OMIM 22410).²⁹ Parents, despite being obligate carriers for a single copy of a mutation, have no symptoms consistent with an EA phenotype or indeed any neurological defects (personal communication with Prof L Al Gazali, United Arab Emirates University, UAE). Further, the *HSPG* variant lies within the Ig-like C2-type 9 domain. No DDSH or SJS variants have been reported to be located within this domain.

Although *HSPG* is an unlikely candidate, its role in the development of EA cannot be absolutely excluded. One possible

hypothesis for perlecan may involve binding of immunoglobulin-like (Ig-like) repeats in perlecan ($n = 22$) and those in ion channel proteins. The *HSPG2* variant in this family is located in domain IV of the protein, which contains 22 Ig-like domains. Such interactions have already been proposed (Kirn–Safran *et al*³⁰). The voltage-gated sodium channels in rats are composed of a one alpha and two beta subunits. The beta subunits are both predicted to form Ig folds in their extracellular domains.³¹ The deletion of the extracellular domain of the beta-1 prevents sodium channel modulation.³² Beta-1 knockout mice develop an ataxic gait and frequent generalized seizures that are followed by periods of immobility.³³ Mutations in sodium channel alpha subunit genes have already been reported to cause complex neurological phenotypes that include ataxia including *SCN2A*³⁴ and *SCN8A*.³⁵

The *UBR4* gene encodes an ubiquitin-protein ligase that interacts in the nucleus with the retinoblastoma-associated protein. In the cytoplasm, it has been localized to and shown to interact with the smooth endoplasmic reticulum in neurons.³⁶ These are known to be a major intracellular calcium store. It has also been shown to interact with calcium bound calmodulin in the cytoplasm,³⁷ highlighting the potential role for *UBR4* in calcium signaling. Calmodulin has its role in calcium signaling through calcium-dependent inactivation or calcium-dependent facilitation.^{38,39} It has been shown to bind and act as a regulator of neural excitability in *KCNQ*⁴⁰ and *Cav2.1* channels (see Halling *et al* for a recent review⁴¹). The *CACNA1A* gene encodes the *Cav2.1* channel, and it is mutations in this gene that cause the most common form of EA (EA2). The ataxic mouse model ('Pogo') has shown to have altered purkinje cell responses and calmodulin content.⁴² Nakatani *et al*³⁷ hypothesized that *UBR4* may act as a sensor of Ca^{2+} , which is released through *ITPR1*, an inositol triphosphate receptor. *ITPR1* is an intracellular calcium-release channel gated by IP₃ (inositol 1,4,5-triphosphate), and purkinje cells have dense concentrations of *ITPR1* on their post-synaptic endoplasmic reticuli.⁴³ *ITPR1* is a major determinant of motor coordination in mammals and may well be the 'centre of the storm' with regard to the development of ataxic disorders in addition to other neurological conditions (see Schorge *et al*⁴⁴ for a recent review). Null and missense mutations of *ITPR1* can result in SCA15.⁴⁵ Reduced *ITPR1* expression was reported in post-mortem study of the cerebellums of two patients with ataxia.⁴⁶ In addition, *ITPR1* has been reported to be a binding protein for CA8. Mutations in the gene encoding this protein can lead to congenital cerebellar ataxia and mild mental retardation (OMIM 613227). A mouse model (the 'waddles' mouse) develops ataxia, appendicular dystonia and abnormal ambulation as a result of a 19bp deletion in exon 8.⁴⁷ It is possible that atypical binding of *UBR4* with calmodulin and/or *ITPR1* may result in an abnormal calcium sensor system within the neuron and hence the development of ataxia. These reported findings highlight an interesting possible role of *UBR4* in the development of ataxia.

In summary, we present the clinical details of a family presenting with a novel form of episodic ataxia. Utilizing linkage analysis, we report a previously unreported locus on chromosome 1p36.13–p34.3. Furthermore, next-generation sequencing has identified two potential disease-causing variants. The first lies in the *HSPG2* gene (S2380R). The second variant lies in the *UBR4* gene (R5091H). This gene is known to interact with calmodulin, a calcium sensor protein, which has been previously reported to be a regulator of the *Cav2.1* channel. These findings highlight a novel candidate gene for EA.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

The authors of this paper would like to thank the family members who participated in the research. We would also like to thank Ataxia Ireland for funding this project. We also thank L Al Gazali for providing additional clinical data related to her patients.

- 1 Brandt T, Strupp M: Episodic ataxia type 1 and 2 (familial periodic ataxia/vertigo). *Audiol Neurootol* 1997; **2**: 373–383.
- 2 Jen J, Kim GW, Baloh RW: Clinical spectrum of episodic ataxia type 2. *Neurology* 2004; **62**: 17–22.
- 3 Escayg A, De Waard M, Lee DD *et al*: Coding and noncoding variation of the human calcium-channel beta4-subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia. *Am J Hum Genet* 2000; **66**: 1531–1539.
- 4 Jen JC, Wan J, Palos TP, Howard BD, Baloh RW: Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures. *Neurology* 2005; **65**: 529–534.
- 5 Gardiner AR, Bhatia KP, Stamelou M *et al*: PRRT2 gene mutations: from paroxysmal dyskinesia to episodic ataxia and hemiplegic migraine. *Neurology* 2012; **79**: 2115–2121.
- 6 Labate A, Tarantino P, Viri M *et al*: Homozygous c.649dupC mutation in PRRT2 worsens the BFIS/PKD phenotype with mental retardation, episodic ataxia, and absences. *Epilepsia* 2012; **53**: e196–e199.
- 7 Stelzl U, Worm U, Lalowski M *et al*: A human protein-protein interaction network: a resource for annotating the proteome. *Cell* 2005; **122**: 957–968.
- 8 Cader MZ, Steckley JL, Dymant DA, McLachlan RS, Ebers GC: A genome-wide screen and linkage mapping for a large pedigree with episodic ataxia. *Neurology* 2005; **65**: 156–158.
- 9 Purcell S, Neale B, Todd-Brown K *et al*: PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007; **81**: 559–575.
- 10 Abecasis GR, Cherny SS, Cookson WO, Cardon LR: Merlin-rapid analysis of dense genetic maps using sparse gene flow trees. *Nat Genet* 2002; **30**: 97–101.
- 11 Li H, Durbin R: Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 2009; **25**: 1754–1760.
- 12 McKenna A, Hanna M, Banks E *et al*: The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* 2010; **20**: 1297–1303.
- 13 Li H, Handsaker B, Wysoker A *et al*: The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 2009; **25**: 2078–2079.
- 14 Wang K, Li M, Hakonarson H: ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res* 2010; **38**: e164.
- 15 Adzhubei IA, Schmidt S, Peshkin L *et al*: A method and server for predicting damaging missense mutations. *Nat Methods* 2010; **7**: 248–249.
- 16 Kumar P, Henikoff S, Ng PC: Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc* 2009; **4**: 1073–1081.
- 17 Bromberg Y, Rost B: SNAP: predict effect of non-synonymous polymorphisms on function. *Nucleic Acids Res* 2007; **35**: 3823–3835.
- 18 Ferrer-Costa C, Gelpi JL, Zamakola L, Parraga I, de la Cruz X, Orozco M: PMUT: a web-based tool for the annotation of pathological mutations on proteins. *Bioinformatics* 2005; **21**: 3176–3178.
- 19 Munthe-Fog L, Hummelshoj T, Ma YJ *et al*: Characterization of a polymorphism in the coding sequence of FCN3 resulting in a Ficolin-3 (Hakata antigen) deficiency state. *Mol Immunol* 2008; **45**: 2660–2666.
- 20 Eguchi H, Tsujino A, Kaibara M *et al*: Acetazolamide acts directly on the human skeletal muscle chloride channel. *Muscle Nerve* 2006; **34**: 292–297.
- 21 Gordon N: Episodic ataxia and channelopathies. *Brain Dev* 1998; **20**: 9–13.
- 22 Bisdorff AR: Management of vestibular migraine. *Ther Adv Neurol Disord* 2011; **4**: 183–191.
- 23 Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. *Acta Neurol Scand* 2008; **118**: 69–86.
- 24 Taft WC, DeLorenzo RJ: Micromolar-affinity benzodiazepine receptors regulate voltage-sensitive calcium channels in nerve terminal preparations. *Proc Natl Acad Sci USA* 1984; **81**: 3118–3122.
- 25 Wan J, Mamsa H, Johnston JL *et al*: Large Genomic Deletions in CACNA1A Cause Episodic Ataxia Type 2. *Front Neurol* 2011; **2**: 51.
- 26 Koh SH, Kim HT, Kim SH, Lee GY, Kim J, Kim MH: Spinocerebellar ataxia type 6 and episodic ataxia type 2 in a Korean family. *J Korean Med Sci* 2001; **16**: 809–813.
- 27 Nicole S, Davoine CS, Topaloglu H *et al*: Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia). *Nat Genet* 2000; **26**: 480–483.
- 28 Stum M, Davoine CS, Vicart S *et al*: Spectrum of HSPG2 (Perlecan) mutations in patients with Schwartz-Jampel syndrome. *Hum Mutat* 2006; **27**: 1082–1091.
- 29 Arikawa-Hirasawa E, Wilcox WR, Le AH *et al*: Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perlecan gene. *Nat Genet* 2001; **27**: 431–434.
- 30 Kirn-Safran C, Farach-Carson MC, Carson DD: Multifunctionality of extracellular and cell surface heparan sulfate proteoglycans. *Cell Mol Life Sci* 2009; **66**: 3421–3434.
- 31 Isom LL, Ragsdale DS, De Jongh KS *et al*: Structure and function of the beta 2 subunit of brain sodium channels, a transmembrane glycoprotein with a CAM motif. *Cell* 1995; **83**: 433–442.
- 32 McCormick KA, Isom LL, Ragsdale D, Smith D, Scheuer T, Catterall WA: Molecular determinants of Na⁺ channel function in the extracellular domain of the beta1 subunit. *J Biol Chem* 1998; **273**: 3954–3962.
- 33 Chen C, Westenbroek RE, Xu X *et al*: Mice lacking sodium channel beta1 subunits display defects in neuronal excitability, sodium channel expression, and nodal architecture. *J Neurosci* 2004; **24**: 4030–4042.
- 34 Liao Y, Anttonen AK, Liukkonen E *et al*: SCN2A mutation associated with neonatal epilepsy, late-onset episodic ataxia, myoclonus, and pain. *Neurology* 2010; **75**: 1454–1458.
- 35 Trudeau MM, Dalton JC, Day JW, Ranum LP, Meisler MH: Heterozygosity for a protein truncation mutation of sodium channel SCN8A in a patient with cerebellar atrophy, ataxia, and mental retardation. *J Med Genet* 2006; **43**: 527–530.
- 36 Shim SY, Wang J, Asada N *et al*: Protein 600 is a microtubule/endoplasmic reticulum-associated protein in CNS neurons. *J Neurosci* 2008; **28**: 3604–3614.
- 37 Nakatani Y, Konishi H, Vassilev A *et al*: p600, a unique protein required for membrane morphogenesis and cell survival. *Proc Natl Acad Sci USA* 2005; **102**: 15093–15098.
- 38 DeMaria CD, Soong TW, Alseikhan BA, Alvania RS, Yue DT: Calmodulin bifurcates the local Ca²⁺ signal that modulates P/Q-type Ca²⁺ channels. *Nature* 2001; **411**: 484–489.
- 39 Liang H, DeMaria CD, Erickson MG, Mori MX, Alseikhan BA, Yue DT: Unified mechanisms of Ca²⁺ regulation across the Ca²⁺ channel family. *Neuron* 2003; **39**: 951–960.
- 40 Shahidullah M, Santarelli LC, Wen H, Levitan IB: Expression of a calmodulin-binding KCNQ2 potassium channel fragment modulates neuronal M-current and membrane excitability. *Proc Natl Acad Sci USA* 2005; **102**: 16454–16459.
- 41 Halling DB, Aracena-Parks P, Hamilton SL: Regulation of voltage-gated Ca²⁺ channels by calmodulin. *Sci STKE* 2005; : re15.
- 42 Lee KY, Kim JS, Kim SH *et al*: Altered Purkinje cell responses and calmodulin expression in the spontaneously ataxic mouse, Pogo. *Eur J Neurosci* 2011; **33**: 1493–1503.
- 43 Bardo S, Cavazzini MG, Emptage N: The role of the endoplasmic reticulum Ca²⁺ store in the plasticity of central neurons. *Trends Pharmacol Sci* 2006; **27**: 78–84.
- 44 Schorge S, van de Leemput J, Singleton A, Houlden H, Hardy J: Human ataxias: a genetic dissection of inositol triphosphate receptor (ITPR1)-dependent signaling. *Trends Neurosci* 2010; **33**: 211–219.
- 45 van de Leemput J, Chandran J, Knight MA *et al*: Deletion at ITPR1 underlies ataxia in mice and spinocerebellar ataxia 15 in humans. *PLoS Genet* 2007; **3**: e108.
- 46 Zecevic N, Milosevic A, Ehrlich BE: Calcium signaling molecules in human cerebellum at midgestation and in ataxia. *Early Hum Dev* 1999; **54**: 103–116.
- 47 Jiao Y, Yan J, Zhao Y *et al*: Carbonic anhydrase-related protein VIII deficiency is associated with a distinctive lifelong gait disorder in waddles mice. *Genetics* 2005; **171**: 1239–1246.

Supplementary Information accompanies this paper on European Journal of Human Genetics website (<http://www.nature.com/ejhg>)